Special Issue "Molecular Profiling of Lung Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 March 2019
Dr. Kentaro Inamura
Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
Website | E-Mail
Interests: molecular/surgical pathology; lung cancer; urological (kidney, prostate, urinary bladder) cancer; colorectal cancer; microRNA; non-coding RNA
High-throughput technologies have enabled the molecular profiling of lung cancer, allowing for refined risk assessments, as well as the development of non-invasive screening methods or therapeutic interventions for lung cancer. The objective of this Special Issue is to publish the latest findings in the molecular profiling/signatures of lung cancer aimed toward clinical implementation.
Topics of this Special Issue include, but are not limited to:
- Molecular profiling/signatures that can classify lung cancers into specific subtypes with different clinical outcomes or sensitivities to specific treatments (e.g., molecular-targeted therapy, immune checkpoint inhibitor, neoadjuvant chemotherapy, and so forth). Molecular characteristics related to sensitivity to immunotherapy are of interest.
- Molecular profiling/characterization of specific lung cancer subtypes: Adenocarcinoma with specific driver mutations may develop, progress, or metastasize via specific molecular pathways.
- Molecular profiling/signatures that allow the determination of useful biomarkers for liquid biopsy. Liquid biopsy is an emerging and promising non-invasive screening method.
- Molecular profiling/signatures that allow the determination of key molecules in specific pathways (e.g., downstream pathway of multiple classes of growth factor receptors).
- Molecular profiling/signatures that allow the determination of biomarkers for specific clinicopathological characteristics (e.g., clinical outcomes).
- Molecular profiling/signatures that allow the determination of biomarkers for acquired resistance to specific drugs (e.g., tyrosine kinase inhibitors, immune checkpoint inhibitors, and so forth).
- Molecular profiling/signatures of the normal-looking lung tissue surrounding the lung cancer (field cancerization).
Target topics (examples are described above) are comprehensive and will give a thorough view of the increasing knowledge of molecular profiling/signatures of lung cancer.
Dr. Kentaro Inamura
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.